Issues related to access to contraceptives. Issues related to drug pricing.
Issues related to drug pricing. Medicare coverage policies and issues impacting the pharmaceutical industry including 340b program.
Monitoring issues related to US and international tax code.
Monitoring activities related to trade.
Support for workforce training at community clinics.
Duration: January 1, 2008
to
October 1, 2023
General Issues: Health Issues , Medicare/Medicaid , Taxation/Internal Revenue Code , Trade (Domestic & Foreign) , Budget/Appropriations , Chemicals/Chemical Industry
Spending: about $1,630,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2008: U.S. Senate, House of Representatives
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Karina Lynch Staff, Senate Special Committee on Aging
Staff, Senate Special Committee on Aging; Staff,
Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov. Affairs
Susan Hirschmann COS, Rep.Van Hilleary & Majority Whip
COS, Rep. Tom DeLay and Rep. Van Hilleary
COS, Rep. Van Hilleary and Majority Whip Tom DeLay
Jenny DiJames LA and LD, Rep. Bud Cramer
LA and LD, Congressman Bud Cramer
Michael Beer LA, Rep. Dave Hobson
LA, Congressman Dave Hobson
Christopher Hatcher Sch. C, Treasury; LD, Rep. Scott McInnis
Sch. C, Treasury; Associate Staff, House Rules Committee; LD, Rep. Scott McInnis
Anthony Roda Leadership Staff, House Whip Gingrich
Joyce Rogers Rep. Steny Hoyer and Rep. Corrine Brown
Rep. Steny Hoyer & Rep. Corrine Brown
Karina Lynch continued Staff, Senate Committee on Government Affairs
Prmnt. Subcmte on Invstigations; Staff, Govt.Affair
Laura Simmons Advisor, Office of Legislative Affairs, Dept of Homeland Security
Ann Marie Buerkle Member of Congress; Commissioner, Acting-Chair at CPSC
Cheryl Jaeger Shared employee, Ofc of the Speaker & Ofc of VA 07; Sr Policy Adv, Maj Leader, Rep. Cantor; Sr Policy Adv, Republican Whip, Rep. Cantor; Sr Policy Adv, Majority Whip, Rep. Blunt; Prof Staff House Committee on E & C; Sr LA to Rep. Cox
George Olsen n/a
J.Steven Hart n/a
Matthew Hoekstra n/a
Melinda Maxfield n/a
Erin Book n/a
Tess Illos n/a
Robert Martinez n/a
J. Steven Hart n/a
Bob Martinez n/a
Nicole Bertsch n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2023
Williams and Jensen, PLLC terminated an engagement in which they represented BAYER CORPORATION on Jan. 19.
Original Filing: 301532374.xml
3rd Quarter, 2023
In Q3, Williams and Jensen, PLLC did no lobbying for BAYER CORPORATION . The report was filed on Oct. 20, 2023.
Original Filing: 301512837.xml
2nd Quarter, 2023
In Q2, Williams and Jensen, PLLC lobbied for BAYER CORPORATION , earning $80,000. The report was filed on July 20, 2023.
Original Filing: 301489218.xml
Lobbying Issues
Issues related to access to contraceptives. Issues related to drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing. Medicare coverage policies and issues impacting the pharmaceutical industry including 340b program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitoring issues related to US and international tax code.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitoring activities related to trade.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Support for workforce training at community clinics.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2023
In Q1, Williams and Jensen, PLLC lobbied for BAYER CORPORATION , earning $80,000. The report was filed on April 20, 2023.
Original Filing: 301462999.xml
Lobbying Issues
Issues related to access to contraceptives. Issues related to drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing. Medicare coverage policies and issues impacting the pharmaceutical industry including 340b program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitoring issues related to US and international tax code.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitoring activities related to trade.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Support for workforce training at community clinics.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2022
In Q4, Williams and Jensen, PLLC lobbied for BAYER CORPORATION , earning $80,000. The report was filed on Jan. 20, 2023.
Original Filing: 301440561.xml
Lobbying Issues
Issues related to access to contraceptives. Issues related to drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing. Medicare coverage policies and issues impacting the pharmaceutical industry including 340b program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitoring issues related to US and international tax code.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitoring activities related to trade.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2022
In Q3, Williams and Jensen, PLLC lobbied for BAYER CORPORATION , earning $80,000. The report was filed on Oct. 20, 2022.
Original Filing: 301415622.xml
Lobbying Issues
Issues related to access to contraceptives. Issues related to drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing. Medicare coverage policies and issues impacting the pharmaceutical industry including 340b program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitoring issues related to US and international tax code.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitoring activities related to trade.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2022
Williams and Jensen, PLLC filed a lobbying registration on Aug. 10, 2022 to represent BAYER CORPORATION, effective July 1, 2022.
Original Filing: 301398767.xml
Issue(s) they said they’d lobby about: Issues related to access to contraceptives. Issues related to drug pricing. Medicare coverage policies and issues impacting the pharmaceutical industry including 340b program. Monitoring activities related to trade. Monitoring issues related to US and international tax code. .
1st Quarter, 2015
Williams and Jensen, PLLC terminated an engagement in which they represented BAYER CORPORATION on April 14, 2015.
Original Filing: 300715026.xml
4th Quarter, 2014
In Q4, Williams & Jensen, PLLC. lobbied for BAYER CORPORATION , earning $20,000. The report was filed on Jan. 15, 2015.
Original Filing: 300696220.xml
Lobbying Issues
Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Prescription drug advertising; Federal preemption for prescription drugs; Implementation of Patient Protection and Affordable Care Act; drug shortages; Work on 21st Century Cures Initiative.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Drug rebates for Medicare Part D; Independent Payment Advisory Board (IPAB).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues affecting R&D tax credit.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2014
In Q3, Williams & Jensen, PLLC. lobbied for BAYER CORPORATION , earning $80,000. The report was filed on Oct. 20, 2014.
Original Filing: 300682951.xml
Lobbying Issues
Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Prescription drug advertising; Federal preemption for prescription drugs; Implementation of Patient Protection and Affordable Care Act; drug shortages; Work on 21st Century Cures Initiative.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare payment for diabetes testing strips; Drug rebates for Medicare Part D; Independent Payment Advisory Board (IPAB); Work on resolution commemorating self-care.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2014
In Q2, Williams & Jensen, PLLC. lobbied for BAYER CORPORATION , earning $60,000. The report was filed on July 18, 2014.
Original Filing: 300661991.xml
Lobbying Issues
Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Prescription drug advertising; Federal preemption for prescription drugs; Implementation of Patient Protection and Affordable Care Act; drug shortages.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare payment for diabetes testing strips. Drug rebates for Medicare Part D. Independent Payment Advisory Board (IPAB). Work on resolution commemorating self-care.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2014
In Q1, Williams & Jensen, PLLC. lobbied for BAYER CORPORATION , earning $30,000. The report was filed on April 17, 2014.
Original Filing: 300638501.xml
Lobbying Issues
Drug safety and drug counterfeiting (track and trace); Drug importation; 340B Program; Authorized generics; Prescription drug advertising; Federal preemption for prescription drugs; Implementation of Patient Protection and Affordable Care Act; drug shortages.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare payment for diabetes testing strips. Drug rebates for Medicare Part D. Independent Payment Advisory Board (IPAB).
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2013
In Q4, Williams & Jensen, PLLC. lobbied for BAYER CORPORATION , earning $40,000. The report was filed on Jan. 16, 2014.
Original Filing: 300616536.xml
Lobbying Issues
Drug safety and drug counterfeiting (track and trace); Drug importation; 340B Program; Authorized generics; Prescription drug advertising; Federal preemption for prescription drugs; Implementation of Patient Protection and Affordable Care Act; drug shortages.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare payment for diabetes testing strips. Drug rebates for Medicare Part D. Independent Payment Advisory Board (IPAB). House and Senate action on H.J. Res. 59 and possible drug industry issues.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2013
In Q3, Williams & Jensen, PLLC. lobbied for BAYER CORPORATION , earning $50,000. The report was filed on Oct. 18, 2013.
Original Filing: 300598804.xml
Lobbying Issues
Drug safety and drug counterfeiting (track and trace); Drug importation; 340B Program; Authorized generics; Prescription drug advertising; Federal preemption for prescription drugs; Implementation of Patient Protection and Affordable Care Act; drug shortages.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare payment for diabetes testing strips; drug rebates for Medicare Part D. Independent Payment Advisory Board (IPAB). House and Senate Budget resolutions.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2013
In Q2, Williams & Jensen, PLLC. lobbied for BAYER CORPORATION , earning $70,000. The report was filed on July 19, 2013.
Original Filing: 300578439.xml
Lobbying Issues
Drug safety and drug counterfeiting (track and trace); Drug importation; 340B Program; Authorized generics; Prescription drug advertising; Federal preemption for prescription drugs; Implementation of Patient Protection and Affordable Care Act; drug shortages.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare payment for diabetes testing strips; drug rebates for Medicare Part D. Independent Payment Advisory Board (IPAB). House and Senate Budget resolutions.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2013
In Q1, Williams & Jensen, PLLC. lobbied for BAYER CORPORATION , earning $20,000. The report was filed on April 22, 2013.
Original Filing: 300559627.xml
Lobbying Issues
Drug safety and drug counterfeitingv (track and trace); Drug importation; 340B Program; Authorized generics; Prescription drug advertising; Federal preemption for prescription drugs; Implementation of Patient Protection and Affordable Care Act; drug shortages.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare payment for diabetes testing strips; drug rebates for Medicare Part D. Independent Payment Advisory Board (IPAB). House and Senate Budget resolutions; Continuing Resolution Appropriations for FY 2013 (H.R. 933)
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2012
In Q4, Williams & Jensen, PLLC. lobbied for BAYER CORPORATION , earning $30,000. The report was filed on Jan. 18, 2013.
Original Filing: 300533409.xml
Lobbying Issues
Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Prescription drug advertising; Federal preemption for prescription drugs; Implementation of Patient Protection and Affordable Care Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare payment for diabetes testing strips; drug rebates for Medicare Part D. Independent Payment Advisory Board (IPAB). American Taxpayer Relief Act of 2012.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, Williams & Jensen, PLLC. lobbied for BAYER CORPORATION , earning $70,000. The report was filed on Oct. 19, 2012.
Original Filing: 300512481.xml
Lobbying Issues
Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Prescription drug advertising; Federal preemption for prescription drugs; Implementation of Patient Protection and Affordable Care Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare payment for diabetes testing strips; drug rebates for Medicare Part D. Independent Payment Advisory Board (IPAB)
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
In Q2, Williams & Jensen, PLLC. lobbied for BAYER CORPORATION , earning $50,000. The report was filed on July 19, 2012.
Original Filing: 300490003.xml
Lobbying Issues
Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Prescription drug advertising; Federal preemption for prescription drugs; Implementation of Patient Protection and Affordable Care Act; Reauthorization of Prescription Drug User Fee Act and drug shortages (FDA Safety and Innovation Act (S. 3187))
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare payment for diabetes testing strips; drug rebates for Medicare Part D. Independent Payment Advisory Board (IPAB)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Matters concerning safety and security at chemical plants.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Chemicals/Chemical Industry
1st Quarter, 2012
In Q1, Williams & Jensen, PLLC. lobbied for BAYER CORPORATION , earning $30,000. The report was filed on April 20, 2012.
Original Filing: 300471948.xml
Lobbying Issues
Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Prescription drug advertising; Federal preemption for prescription drugs; Implementation of Patient Protection and Affordable Care Act; Reauthorization of Prescription Drug User Fee Act and drug shortages.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare payment for diabetes testing strips.
Drug rebates for Part D. Independent Payment Advisory Board (IPAB)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Matters concerning safety and security at chemical plants.
Type of Issue
Chemicals/Chemical Industry
4th Quarter, 2011
In Q4, Williams & Jensen, PLLC. lobbied for BAYER CORPORATION , earning $70,000. The report was filed on Jan. 20, 2012.
Original Filing: 300448977.xml
Lobbying Issues
Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Drug company settlements including S. 27, Preserve Access to Affordable Generics Act; Prescription drug advertising; Federal preemption for prescription drugs; Legislation concerning civil litigation; and Implementation of Patient Protection and Affordable Care Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare payment for diabetes testing strips.
Drug rebates for Part D.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Matters concerning safety and security at chemical plants.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Chemicals/Chemical Industry
3rd Quarter, 2011
In Q3, Williams & Jensen, PLLC. lobbied for BAYER CORPORATION , earning $20,000. The report was filed on Oct. 20, 2011.
Original Filing: 300425907.xml
Lobbying Issues
Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Drug company settlements including S. 27, Preserve Access to Affordable Generics Act; Prescription drug advertising; Federal preemption for prescription drugs; Legislation affecting telemedicine; Legislation concerning civil litigation; and Implementation of Patient Protection and Affordable
Care Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare payment for diagnostic testing.
Drug rebates for Part D.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Matters concerning safety and security at chemical plants.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Chemicals/Chemical Industry
2nd Quarter, 2011
In Q2, Williams & Jensen, PLLC. lobbied for BAYER CORPORATION , earning $50,000. The report was filed on July 20, 2011.
Original Filing: 300405929.xml
Lobbying Issues
Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Drug company settlements including S. 27, Preserve Access to Affordable Generics Act; Prescription drug advertising; Federal preemption for prescription drugs; Legislation affecting telemedicine; Legislation concerning civil litigation; and Implementation of Patient Protection and Affordable
Care Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare payment for diagnostic testing.
Drug rebates for Part D.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Matters concerning safety and security at chemical plants.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Chemicals/Chemical Industry
1st Quarter, 2011
In Q1, Williams & Jensen, PLLC. lobbied for BAYER CORPORATION , earning $30,000. The report was filed on April 20, 2011.
Original Filing: 300375066.xml
Lobbying Issues
Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Drug company settlements including S. 27, Preserve Access to Affordable Generics Act; Prescription drug advertising; Federal preemption for prescription drugs; Legislation affecting telemedicine; Legislation concerning civil litigation; and Implementation of Patient Protection and Affordable
Care Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare payment for diagnostic testing.
Medicare payment/coverage for telemedicine.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Matters concerning safety and security at chemical plants.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Chemicals/Chemical Industry
4th Quarter, 2010
In Q4, Williams & Jensen, PLLC. lobbied for BAYER CORPORATION , earning $20,000. The report was filed on Jan. 20, 2011.
Original Filing: 300350593.xml
Lobbying Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act;
Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009;
340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act;
Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act;
Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill;
Prescription drug advertising;
Federal preemption for prescription drugs;
Legislation affecting telemedicine; and
Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare payment for diagnostic testing.
Medicare payment/coverage for telemedicine.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Matters concerning safety and security at chemical plants.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Chemicals/Chemical Industry
3rd Quarter, 2010
In Q3, Williams & Jensen, PLLC. lobbied for BAYER CORPORATION , earning $70,000. The report was filed on Oct. 20, 2010.
Original Filing: 300323348.xml
Lobbying Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act;
Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009;
340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act;
Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act;
Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill;
Prescription drug advertising;
Federal preemption for prescription drugs;
Legislation affecting telemedicine; and
Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare payment for diagnostic testing.
Medicare payment/coverage for telemedicine.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Matters concerning safety and security at chemical plants.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Chemicals/Chemical Industry
2nd Quarter, 2010
In Q2, Williams & Jensen, PLLC. lobbied for BAYER CORPORATION , earning $40,000. The report was filed on July 15, 2010.
Original Filing: 300286951.xml
Lobbying Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act;
Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009;
340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act;
Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act;
Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act;
Prescription drug advertising;
Federal preemption for prescription drugs;
Legislation affecting telemedicine; and
Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare payment for diagnostic testing.
Medicare payment/coverage for telemedicine.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Matters concerning safety and security at chemical plants.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Chemicals/Chemical Industry
1st Quarter, 2010
In Q1, Williams & Jensen, PLLC. lobbied for BAYER CORPORATION , earning $20,000. The report was filed on April 20, 2010.
Original Filing: 300270091.xml
Lobbying Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act;
Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; H.R. 3590, Patient Protection and Affordable Care Act.
Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010.
Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010.
Comparative effectiveness including S. 1259, Preserving Access to Targeted, Individualized, and Effective New Treatments and Services Act of 2009; S. 1213, Patient-Centered Outcomes Research Act of 2009; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010.
Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act;
Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010.
Health care reform including H.R. 3200, America's Affordable Health Choices Act; S.___, Affordable Health Choices Act; and S.___, America's Healthy Future Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010.
Prescription drug advertising;
Federal preemption for prescription drugs;
Legislation affecting telemedicine including H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010.
Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicaid drug rebates including S. 547/H.R. 904, Drug Rebate Equalization Act of 2009; H.R. 1725, Voluntary State Discount Prescription Drug Plan Act of 2009; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010.
Medicare drug price negotiation, payment, and coverage including S. 330/H.R. 684, Medicare Prescription Drug Savings and Choice Act of 2009; S. 266, Medicare Preemption Drug Gap Reduction Act of 2009; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010.
Medicare payment for diagnostic testing;
and Medicare payment/coverage for telemedicine.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Matters concerning safety and security at chemical plants.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Chemicals/Chemical Industry
4th Quarter, 2009
In Q4, Williams & Jensen, PLLC. lobbied for BAYER CORPORATION , earning $100,000. The report was filed on Jan. 20, 2010.
Original Filing: 300242059.xml
Lobbying Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act;
Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009;
Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act;
Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009;
Comparative effectiveness including H.R. 1, the American Recovery and Reinvestment Act; S. 1259, Preserving Access to Targeted, Individualized, and Effective New Treatments and Services Act of 2009; S. 1213, Patient-Centered Outcomes Research Act of 2009;
Health information technology including H.R. 1, the American Recovery and Reinvestment Act;
Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act;
Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act;
Health care reform including H.R. 3200, America's Affordable Health Choices Act; S.___, Affordable Health Choices Act; and S.___, America's Healthy Future Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act;
Prescription drug advertising;
Federal preemption for prescription drugs;
Legislation affecting telemedicine including H.R. 1, the American Recovery and Reinvestment Act; and
Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicaid drug rebates including S. 547/H.R. 904, Drug Rebate Equalization Act of 2009; H.R. 1725, Voluntary State Discount Prescription Drug Plan Act of 2009; Medicare drug price negotiation, payment, and coverage including S. 330/H.R. 684, Medicare Prescription Drug Savings and Choice Act of 2009; S. 266, Medicare Preemption Drug Gap Reduction Act of 2009;
Medicare payment for diagnostic testing;
and Medicare payment/coverage for telemedicine.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Matters concerning safety and security at chemical plants.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Chemicals/Chemical Industry
3rd Quarter, 2009
In Q3, Williams & Jensen, PLLC. lobbied for BAYER CORPORATION , earning $20,000. The report was filed on Oct. 20, 2009.
Original Filing: 300219285.xml
Lobbying Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act;
Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009;
Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act;
Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009;
Comparative effectiveness including H.R. 1, the American Recovery and Reinvestment Act; S. 1259, Preserving Access to Targeted, Individualized, and Effective New Treatments and Services Act of 2009; S. 1213, Patient-Centered Outcomes Research Act of 2009;
Health information technology including H.R. 1, the American Recovery and Reinvestment Act;
Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act;
Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act;
Health care reform including H.R. 3200, America's Affordable Health Choices Act; S.___, Affordable Health Choices Act; and S.___, America's Healthy Future Act;
Prescription drug advertising;
Federal preemption for prescription drugs;
Legislation affecting telemedicine including H.R. 1, the American Recovery and Reinvestment Act; and
Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicaid drug rebates including S. 547/H.R. 904, Drug Rebate Equalization Act of 2009; H.R. 1725, Voluntary State Discount Prescription Drug Plan Act of 2009; Medicare drug price negotiation, payment, and coverage including S. 330/H.R. 684, Medicare Prescription Drug Savings and Choice Act of 2009; S. 266, Medicare Preemption Drug Gap Reduction Act of 2009;
Medicare payment for diagnostic testing;
and Medicare payment/coverage for telemedicine.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Matters concerning safety and security at chemical plants.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Chemicals/Chemical Industry
2nd Quarter, 2009
In Q2, Williams & Jensen, PLLC. lobbied for BAYER CORPORATION , earning $120,000. The report was filed on July 20, 2009.
Original Filing: 300187488.xml
Lobbying Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act;
Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009;
Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act;
Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009;
Comparative effectiveness including H.R. 1, the American Recovery and Reinvestment Act; S. 1259, Preserving Access to Targeted, Individualized, and Effective New Treatments and Services Act of 2009; S. 1213, Patient-Centered Outcomes Research Act of 2009;
Health information technology including H.R. 1, the American Recovery and Reinvestment Act;
Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act;
Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act;
Health care reform including the Affordable Health Choices Act;
Prescription drug advertising;
Federal preemption for prescription drugs;
Legislation affecting telemedicine including H.R. 1, the American Recovery and Reinvestment Act; and
Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicaid drug rebates including S. 547/H.R. 904, Drug Rebate Equalization Act of 2009; H.R. 1725, Voluntary State Discount Prescription Drug Plan Act of 2009; Medicare drug price negotiation, payment, and coverage including S. 330/H.R. 684, Medicare Prescription Drug Savings and Choice Act of 2009; S. 266, Medicare Preemption Drug Gap Reduction Act of 2009;
Medicare payment for diagnostic testing;
and Medicare payment/coverage for telemedicine.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Matters concerning safety and security at chemical plants.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Chemicals/Chemical Industry
1st Quarter, 2009
In Q1, Williams & Jensen, PLLC. lobbied for BAYER CORPORATION , earning $60,000. The report was filed on April 20, 2009.
Original Filing: 300160551.xml
Lobbying Issues
Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009;
Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act;
Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009;
Comparative effectiveness including H.R. 1, the American Recovery and Reinvestment Act;
Health information technology including H.R. 1, the American Recovery and Reinvestment Act;
Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act;
Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act;
Health care reform;
Prescription drug advertising;
Federal preemption for prescription drugs;
Legislation affecting telemedicine including H.R. 1, the American Recovery and Reinvestment Act; and
Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicaid drug rebates including S. 547/H.R. 904, Drug Rebate Equalization Act of 2009; H.R. 1725, Voluntary State Discount Prescription Drug Plan Act of 2009; Medicare drug price negotiation, payment, and coverage including S. 330/H.R. 684, Medicare Prescription Drug Savings and Choice Act of 2009; S. 266, Medicare Preemption Drug Gap Reduction Act of 2009; and Medicare payment for diagnostic testing
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Matters concerning safety and security at chemical plants.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Chemicals/Chemical Industry
4th Quarter, 2008
In Q4, Williams & Jensen, PLLC. lobbied for BAYER CORPORATION , earning $20,000. The report was filed on Jan. 21, 2009.
Original Filing: 300130286.xml
Lobbying Issues
Drug safety/clinical trials; Follow-on biologics; drug advertising; Drug importation and counterfeiting; Physician payment disclosure legislation; Comparative effectiveness; preemption
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Prescription Drug Benefit; Medicaid drug rebate; Medicare payments for diagnostic testing; drug price negotiation; Medicare Improvements for Patients and Physicians Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2008
In Q3, Williams and Jensen lobbied for BAYER CORPORATION , earning $80,000. The report was filed on April 8, 2009.
Original Filing: 300144666.xml
Lobbying Issues
Drug safety/clinical trials; follow-on biologics; drug advertising; drug importation and counterfeiting; physician payment disclosure legislation; comparative effectiveness.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare prescription drug benefit; Medicaid drug rebate; Medicare payments for diagnostic testing; Drug price negotiation; Medicare Improvements for Patients and Physicians Act.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2008
In Q2, Williams & Jensen, PLLC. lobbied for BAYER CORPORATION , earning $20,000. The report was filed on July 17, 2008.
Original Filing: 300069692.xml
Lobbying Issues
Drug Safety/Clinical Trials; Follow-On Biologics; Drug Advertising; Drug Importation and Counterfeiting; S. 2029.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Prescription Drug Benefit; Medicaid drug rebate; Medicare payments for diagnostic testing; drug price negotiation.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2008
In Q1, Williams & Jensen, PLLC. lobbied for BAYER CORPORATION , earning $20,000. The report was filed on April 21, 2008.
Original Filing: 300049659.xml
Lobbying Issues
Drug Safety/Clinical Trials; Follow-On Biologics; Drug Advertising; Drug Importation and Counterfeiting; S. 2029.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Prescription Drug Benefit; Medicaid drug rebate; Medicare payments for diagnostic testing; drug price negotiation.
Agencies Lobbied
U.S. House of Representatives
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...